Siglec15 in blood system diseases: from bench to bedside
2024

Siglec15 in Blood System Diseases

publication Evidence: moderate

Author Information

Author(s): Fan Yujia, Sun Liangliang, He Juan, Chen Yuetong, Ma Hongli, Ding Haitao

Primary Institution: Baotou Medical College of Inner Mongolia University of Science and Technology

Hypothesis

The study reviews the role of Siglec-15 in various blood system diseases and its potential as a therapeutic target.

Conclusion

Siglec-15 is implicated in immune evasion in cancers and may serve as a promising target for immunotherapy in hematological diseases.

Supporting Evidence

  • Siglec-15 is up-regulated in various cancer types, indicating its role in immune evasion.
  • Targeting Siglec-15 may enhance the effectiveness of immunotherapy in hematological malignancies.
  • Siglec-15 can modulate immune responses to microbial infections.

Takeaway

Siglec-15 is a protein that helps cancer cells hide from the immune system, and scientists think it could be a good target for new cancer treatments.

Methodology

The study is a review of existing literature on Siglec-15's biological attributes, expression patterns, and mechanisms in various diseases.

Limitations

The review is based on existing literature and may not include all recent findings or clinical data.

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1490505

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication